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Background: Tumor-associated macrophages (TAMs) have high impact on the cancer development because they
can facilitate matrix invasion, angiogenesis, and tumor cell motility. It gives cancer cells the capacity to invade
normal tissues and metastasize. The signaling of colony-stimulating factor-1 receptor (CSF-1R) which is an important
regulator of proliferation and differentiation of monocytes and macrophages regulates most of the tissue
macrophages. However, CSF-1R is expressed also in breast epithelial tissue during some physiological stages i.g.:
pregnancy and lactation. Its expression has been also detected in various cancers. Our previous study has showed
the expression of CSF-1R in all examined canine mammary tumors. Moreover, it strongly correlated with grade of
malignancy and ability to metastasis. This study was therefore designed to characterize the role of CSF-1R in canine
mammary cancer cells proliferation, apoptosis, migration, and invasion. As far as we know, the study presented
hereby is a pioneering experiment in this field of veterinary medicine.
Results: We showed that csf-1r silencing significantly increased apoptosis (Annexin V test), decreased proliferation
(measured as Ki67 expression) and decreased migration (“wound healing” assay) of canine mammary cancer cells.
Treatment of these cells with CSF-1 caused opposite effect. Moreover, csf-1r knock-down changed growth
characteristics of highly invasive cell lines on Matrigel matrix, and significantly decreased the ability of these cells to
invade matrix. CSF-1 treatment increased invasion of cancer cells.
Conclusion: The evidence of the expression and functional role of the CSF-1R in canine mammary cancer cells
indicate that CSF-1R targeting may be a good therapeutic approach.
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Cancer cell produces various cytokines and chemokines
that attract leukocytes in a similar manner as a site of tis-
sue injury, where monocytes migrate guided by chemotac-
tic factors [1,2]. Tumor-associated macrophages (TAMs)
have high impact on cancer development because they are
educated by the tumor microenvironment to facilitate
matrix invasion, angiogenesis, and tumor cell motility [3].
It gives cancer cells the capacity to invade normal tissues
and metastasize [3,4]. The signaling of colony-stimulating* Correspondence: magdalena_krol@sggw.pl
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reproduction in any medium, provided the orfactor-1 receptor (CSF-1R) which is an important regulator
of proliferation and differentiation of monocytes and mac-
rophages [5] regulates most of the tissue macrophages.
However, CSF-1R is expressed also in breast epithelial tis-
sue during some physiological stages e.g.: pregnancy and
lactation. Its expression is also detected in some cancers
[6] but its role in cancer cell biology is not fully recognized.
Data reported in the literature indicated that the oncogenic
potential of CSF-1R is due to co-expression of this receptor
and its ligand CSF-1 (colony stimulating factor-1) in epi-
thelial cancer cells, or mutations activating CSF-1R inde-
pendently of ligand [7]. Activation of CSF-1R by its ligand
is likely to occur in an autocrine manner in tumor cells in
which CSF-1R and CSF-1 are co-expressed, or in paracrine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fibroblasts [6]. However, our recent studies have shown
that CSF-1R in cancer cells can be stimulated by colony
stimulating factor secreted by tumor-associated macro-
phages [8]. Interestingly, we showed that their co-culture
leads to up-regulation of CSF in macrophages and up-
regulation of CSFs and CSF-1R in cancer cells. These re-
sults are in accordance with the observations that CSF-1R
is important for cancer metastasis but only in the presence
of macrophages [9]. Moreover, our previous study [10] has
shown that the expression of CSF-1R in neoplastic epithe-
lial cells of canine mammary gland strongly correlates with
grade of malignancy and ability to metastasis. This study
was therefore designed to characterize the role of CSF-1R
in canine mammary cancer cells proliferation, apoptosis,
migration, and invasion. As far as we know, the study
presented hereby is a pioneering experiment in this field in
veterinary medicine.Methods
Cell lines
The cell lines used for the study have previously been
used in other published research [8,11-14]. Two canine
mammary adenocarcinoma cell lines (CMT-W1, CMT-W2),
anaplastic cancer cell line (P114), simple carcinoma cell
line (CMT-U27) and spindle-cell mammary tumor
cell line (CMT-U309) were examined. CMT-W1 and
CMT-W2 cell lines were kindly donated by Prof. Dr.
Maciej Ugorski and Dr. Joanna Polanska from Wroclaw
University (Poland), CMT-U27 and CMT-U309 cell lines
were kindly donated by Dr. Eva Hellmen from Swedish
Agricultural University (Sweden) and P114 cell line was
kindly donated by Dr. Gerard Rutteman from Utrecht
University (The Netherlands).
Cells were cultured under optimal conditions: in
RPMI-1640 medium enriched with 10% (v/v) heat-inactivated
fetal bovine serum (FBS), penicillin-streptomycin (50 iU
mL–1), and fungizone (2.5 mg mL–1) (reagents obtained
from Sigma Aldrich, USA), in an atmosphere of 5% CO2
and 95% humidified air at 37°C. At the time of experi-
ments, the culture conditions were changed as follows:
the cells were grown in RPMI-1640 medium without FBS
for 24 hrs, and then the medium was replaced with nor-
mal growth medium supplemented with CSF-1 at the con-
centrations of 25 ng/ml, 50 ng/ml, or 100 ng/ml [6].
Because our previous study [8] showed that adding of
macrophages (secreting CSF-1) to cancer cells culture
(grown in RPMI-1640 medium enriched with 10% FBS)
increased the expression of CSF-1R in cancer cells, and
caused significant changes in their behavior, we conducted
the presently described experiments in a similar manner
(cancer cells grown in full medium) using CSF-1 instead
of macrophages. This experimental model enabled toanswer the question whether macrophages exert their in-
fluence on cancer cells via CSF-1/CSF-1R.
siRNA transfection
The siRNA transfection procedure used in canine mam-
mary cancer cells was described in details in our previously
published study [14]. The cell density, transfection reagent
toxicity and transfection efficacy were optimized according
to the procedure described in our previous manuscript:
[14]. The canine (Canis lupus familiaris) csf-1r sequence
was obtained from Gene Bank with accession number
[XM_546306.3]. The siRNA duplexes were designed by
http://www.sigmaaldrich.com/life-science/custom-oligos/sir
na-oligos/sirna-design-service.html. The results were con-
firmed using two independent algorithms: Dharmacon
(OligoWalk) and Ambion and at last two duplexes were
chosen for further experiments (obtained from Sigma Al-
drich) (1st duplex sequences, are as follow: GUGAGAAG
GUCGAUCUCCAdTdT and UGGAGAUCGACCUUCUC
ACdTdT; 2nd duplex sequences, are as follow: CACAAUC
CCUCAACAAUCUdTdT and AGAUUGUUGAGGGAUU
GUGdTdT). For csf-1r silencing the mixture of both du-
plexes was used (30 pmol + 30 pmol).
All the experiments with transfected cells were con-
ducted 48 hrs after the transfection.
Examination of CSF-1R expression by flow cytometry
Control cells, cells transfected with non-coding and csf-1r
specific siRNA, and cells treated with 25, 50 or 100 ng/ml
CSF-1 (Sigma, USA) were harvested by trypsinization, and
incubated for 1 h in 2% FBS (to block unspecific binding
sites for antibodies). Then the cells were incubated with
10 μl APC-labeled anti-CSF-1R antibody (eBiosciences,
USA) for 1 h at room temperature in the dark. Net, cells
were washed with PBS to remove excess antibody and
then analyzed using BD FACSCAria II (BD Biosciences,
USA) with FACS Diva software (BD Biosciences).
The overlay histograms were created using Flowing Soft-
ware (Turku University, Finland), www.flowingsoftware.
com. The experiment was conducted three times.
Real-time qPCR
Total RNA was isolated using a Total RNA kit (A&A Bio-
technology, Poland) according to the manufacturer’s
protocol. Isolated RNA samples were dissolved in RNase-
free water. The quantity of isolated RNA was measured
using NanoDrop (NanoDrop Technologies, USA). The
mean concentration of RNA was 140 ng/μl, and A260/280
ratio was between 1.8 and 2.0. The samples with adequate
amounts of RNA were treated with DNaseI to eliminate
DNA contamination. The samples were subsequently
purified using RNeasy MiniElute Cleanup Kit (Qiagen). Fi-
nally RNA samples were analyzed on a BioAnalyzer
(Agilent, California, USA) to measure final RNA quality
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ber) > 9 was used for the further analyses.
Primers used to detect the expression of csf-1r gene were
designed using PRIMER3 software (free on-line access) and
checked using Oligo Calculator (free on-line access) and
Primer-Blast (NCBI database). The used sequences were as
follow: TGCAGTTTGGGAAGACTCTC and TGTGGA
CTTCAGCATCTTCA. The optimal annealing time was
4 sec, whereas optimal annealing temperature was 72°C,
the detailed description of the optimal time and tem-
perature conditions for the PCR were describe in our pre-
vious paper [4]. rps19 and hprt genes were used as
non-regulated references for the normalization of target
gene expression. Primers sequences and reaction conditions
were described in our previously published studies [8-10].
Quantitative RT-PCR was performed using fluorogenic
SYBR Green and the Sequence Detection System, Fast
7500 (Applied Biosystems). Data analysis was carried out
using the 7500 Fast System SDS Software Version 1.4.0.25
(Applied Biosystems, USA). The results were analyzed
using comparative Ct method [15]. Relative transcript
abundance of the gene equals ΔCt values (ΔCt =Ctreference–
Cttarget). Relative changes in transcript were calculated as
ΔΔCt values (ΔΔCt =ΔCtnormal conditions–ΔCtsiRNA treated).
The experiment was conducted three times.
Western blot
To assess activation state of the CSF-1R, the Western blot
analyses were conducted. Control cells, cells deprived of
FBS (24 hrs) and cells deprived of FBS and supplemented
with CSF-1 (24 hrs) were subjected to the expression ana-
lysis of p-CSF-1R (Tyr 723) and unfosphorylated form of
this protein.
The cells were pelleted by centrifugation at 400 g at 4°C
for 5 min. Protein extracts from cultured cells were
isolated by lysis of the collected pellets with RIPA buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1% NP-40, 0.25% Na-deoxycholate and 1 mM PMSF)
supplemented with protease inhibitor cocktail (Sigma-
Aldrich) and phosphatase inhibitor cocktail (Sigma-
Aldrich) for 30 min at 4°C. Lysates were cleared for
20 min at 14000 rpm, and supernatants were collected.
Protein concentration in the lysates was determined by
Bio-Rad Protein Assay Dye (Bio-Rad Laboratories Inc.,
USA). Proteins (50 μg) were resolved by SDS-PAGE
and transferred onto PVDF membrane (Sigma-Aldrich).
For immunostaining the membranes were blocked
with 5% nonfat dry milk in TBS, containing 0.5% Tween
20. The membranes were incubated with primary anti-
bodies: p-CSF-1R (Tyr 723) (Bioss, USA) (1:200) and
unphosphorylated CSF-1R (Abcam, UK) (1:200) at 4°C
overnight. After the incubation, the membranes were
washed 3 times in 1x TBS containing 0.5% Tween 20 and
incubated for 1 h at room temperature with secondaryantibodies conjugated with appropriate IR fluorophores:
IRDyeW 800 CW (IR- longer-wavelength near-infrared)
(1:5000 dilution). Odyssey Infrared Imaging System
(LI-COR Biosciences) was used to analyze the protein ex-
pression. Scan resolution of the instrument was set at
169 μm and the intensity at 4. Quantification of the inte-
grated optical density (IOD) was performed with the ana-
lysis software provided with the Odyssey scanner (LI-COR
Biosciences, USA). To remove antibodies, membranes were
incubated 15 min at RT in Restore Western Blot Stripping
Buffer (Thermo Scientific, USA). The optical density of
band reflecting p-CSF-1R expression was calculated versus
band reflecting unphosphorylated CSF-1R expression. This
experiment was conducted at least in triplicate.
Immunohistochemistry
The activation status of CSF-1R was also assessed
immunohistochemically. The control cells, cells deprived of
FBS (24 hrs) and cells deprived of FBS and supplemented
with CSF-1 (24 hrs) were cultured on 4-chambers Lab Tek
(Nunc Inc., Denmark) and fixed with 70% ethanol. After
washing with TRIS (Dako) the samples were incubated in
Peroxidase Blocking Reagent (Dako) for 10 min at room
temperature. After 30 min incubation in 5% bovine serum
albumin (Sigma Aldrich) the rabbit polyclonal anti- p-CSF
-1R (Tyr 723) antibodies (Bioss, USA) diluted in 1% bovine
serum were used, and then the slides were incubated
at +4°C overnight. For the staining the EnVision kit (Dako)
was used (Labelled Polymers consist of secondary anti-
rabbit antibodies conjugated with the Horseradish pero-
xidase-HRP enzyme complex). To develop the colored
product the 3,30-Diaminobenzidine (DAB) substrate (Dako)
was used. Finally, the haematoxylin was used for nuclei
counterstaining.
For immunohistochemical experiment, the negative con-
trol samples stained without the use of primary antibo-
dies were set aside. Four independent experiments were
conducted.
Ten pictures of each slide were taken using Olympus
microscopy BX60. The colorimetric intensity of the IHC-
stained antigen (brown precypitate) was counted by a
computer-assisted image analyzer (Olympus Microimage™
Image Analysis, software version 4.0 for Windows, USA).
The antigen spot color intensity is expressed as mean pixel
Integrated Optical Density (IOD).
Apoptosis assay
The Annexin V-FITC and propidium iodide (PI) dual
staining was applied for apoptosis analysis. Control cells
and cells treated with: (1) non-coding siRNA and transfec-
tion reagent, (2) csf-1r specific siRNA, (3) CSF-1, were
harvested by trypsinization. These cells, as well as the cells
floating in medium (RPMI 1640 containing 10% FBS) were
stained using an Annexin V Kit (Becton Dickinson, USA),
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analyzed by flow cytometer (BD FACS Aria II, Becton
Dickinson, USA) within 1 h after staining. Early apoptotic
cells with exposed phosphatidylserine but intact cell mem-
branes bound to Annexin V-FITC but excluded PI. Cells
in late apoptotic stages were labeled with both Annexin
V-FITC and PI, whereas necrotic cells were labeled with
PI only. All samples were assayed in triplicate. The experi-
ment was conducted twice.
Ki-67 expression analysis
The expression of nuclear antigen Ki-67 was measured.
Ki-67 is an antigen expressed by cells, which are in the ac-
tive phases of cell cycle (in each phase except G0). Control
cells and cells treated with: (1) non-coding siRNA and
transfection reagent, (2) csf-1r specific siRNA, (3) CSF-1,
were harvested by trypsinization. These cells, as well as
the cells floating in medium (RPMI 1640 containing 10%
FBS) were fixed in ice-cold ethanol (70%). After fixation,
cells were incubated with FITC conjugated anti Ki-67 anti-
bodies (clone B56), or control isotype immunoglobulin
IgG1, ĸ (Becton Dickinson). Nuclei were stained with
propidium iodide (PI) (Sigma) according to the manufac-
turer’s protocol. The cells were analyzed using FACS Aria
II (Becton Dickinson). All samples were assayed in tripli-
cate. The experiment was conducted twice.
Wound-healing assay
To assess the role of CSF-1R in migration of cancer cells
we applied a wound-healing test. The cancer cells (con-
trol cells, transfected and CSF-1 treated) were separately
seeded in multi-well plates and cultured in RPMI 1640
containing 10% FBS, until reaching confluence, and then
a straight scratch (simulating a wound) was made using a
pipette tip (100 ul). The images were captured at the be-
ginning of the test and at regular intervals (after 2, 4 and
6 hours) during cell migration to close the wound. Then
the images were compared to quantify migration rate of
the cells. This method is particularly suitable to study the
cell-cell interactions and cell migration [16]. The pictures
were analyzed using a computer-assisted image analyzer
(Olympus Microimage™ Image Analysis, software ver-
sion 4.0 for Windows, USA). All samples were assayed in
duplicate. The experiment was conducted three times.
3D culture
Cancer control cells and cells treated with: (1) non-coding
siRNA and transfection reagent, (2) csf-1r specific siRNA,
(3) CSF-1 were treated with trypsin and resuspended in
culture medium (RPMI 1640 containing 10% FBS). 35 mm
culture plates (Corning Inc.) were coated with 100 μl of
growth factor reduced Matrigel (BD Biosciences) and left
to solidify for 30 min. at 37°C. The cells were then plated
at a concentration of 104 cells/ml. The growth of cells onMatrigel was observed everyday under phase-contrast
microscope. The experiment was conducted three times.
Invasion assay
BD BioCoat Matrigel™ invasion chambers (BD Biosciences,
USA) pre-coated with BD Matrigel matrix were used
according to the manufacturer’s protocol. The assay insert
plates were prepared by rehydrating the BD Matrigel
Matrix coating with phosphate buffered saline for two
hours at 37°C. The rehydration solution was carefully re-
moved, 2.5x105 of control cancer cells, transfected cells and
CSF-1 treated cells suspended in RPMI 1640 medium with-
out FBS were added separately onto the apical chambers,
and 0.75 ml of RPMI-1640 containing chemoattractant
(10% FBS) was added to the basal chambers. Uncoated in-
sert plates, included as invasion controls, were used without
rehydration. Assay plates were incubated for 22 hrs at
standard culturing conditions. 2.5 μg/ml Calcein AM were
added to 20 μl DMSO and then, 10 μl was transferred to
12 ml Hanks Buffered Saline Dispense. 0.5 ml Calcein solu-
tion was then transferred into each well of 24-well plate.
The medium from insert was removed and multiwell in-
serts were transferred to the plate containing 0.5 ml/well
calcein. Plates were incubated for 1 h at standard culture
conditions. The fluorescence of invaded cells was mea-
sured with excitation wave length 485 nm and emission
wave length Em 530 nm using Tecan Infinite 200 Rea-
der (Tecan). Each condition (cell line and treatment)
was assayed three times. The experiment was conducted
three times.
Statistical analysis
The analysis for statistical purposes was conducted using
Prism version 5.00 software (GraphPad Software, USA).
The one-way ANOVA and Tukey HSD (Honestly Sig-
nificant Difference) post-hoc test, Dunnett’s test and
t-test were applied as well as regression analysis. The
p-value <0.05 was regarded as significant, whereas,
p-value <0.01 and p-value <0.001 as highly significant.
The data was expressed as means +/− S.D. The in vitro
wound healing assay was analyzed using two-way RM
ANOVA and Bonferroni post-hoc test.
Results
Expression of colony stimulating factor receptor 1 in
examined cell lines
The expression of CSF-1R at protein level was detected
in all examined cell lines (58.7-88.7% of cells expressing
CSF-1R), which confirmed our previously published re-
sults [8]. We did not observe any correlation between cell
line characteristics and the level of CSF-1R expression.
Flow cytometric analysis demonstrated that treatment of
cells with csf-1r specific siRNA significantly decreased
the number of cells expressing CSF-1R in all lines. The
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knockdown was observed in CMT-U309 cell line (3.0%).
At the same time, treatment of cells with scrambled
(non-specific) siRNA did not cause any changes in
CSF-1R expression which remained equivalent to that of
non-transfected control cells. Similarly, culture of cancer
cells in serum-starved conditions (RPMI-1640 without
addition of FBS) did not affect the number of cells express-
ing CSF-1R. Analysis using flow cytometry revealed that
supplementation of cell cultures with CSF-1 (25 ng/ml,
50 ng/ml or 100 ng/ml) significantly increased the num-
ber of cells expressing CSF-1R (Table 1, Figure 1). How-
ever, this effect was not dose-dependent, as all used
doses caused similar effect (more than 99% of cells ex-
pressing CSF-1R).
Furthermore, analysis of mean fluorescence related to
CSF-1R expression revealed that its expression in cells
treated with csf-1r specific siRNA decreased 1.5-9.44 fold
(Table 2, Figure 1), whereas, in cells treated with CSF-1
the expression increased 5.55-20.05 fold. No significant
differences in the number of cells expressing CSF-1R, and
its mean expression were noted between the cells exposed
to different CSF-1 doses, therefore, in all further experi-
ments the lowest dose was used (25 ng/ml). Cancer cells
culture in serum-starved conditions (RPMI-1640 with-
out addition of FBS) decreased the mean expression of
CSF-1R 1.17-2.29 fold (Table 2).
Real-time PCR analysis confirmed a significant decrease
in the level of csf-1r mRNA in all cell lines treated with
csf-1r -specific siRNA, whereas the expression of this re-
ceptor was significantly increased in all the cell lines
treated with CSF-1 (Figure 2).
Western blot and immunohistochemical analyses of
CSF-1R activation showed that in cells deprived of serum,
phosphorylation of CSF-1R (Tyr 723) significantly de-
creased (Figures 3 and 4), whereas in cells deprived of
serum but supplemented in CSF-1 (25 ng/ml) CSF-1R ac-
tivation significantly increased (Figures 3 and 4). The
highest level of CSF-1R activation upon CSF-1 treatment
was observed in CMT-U309, CMT-U309 and P114 cell
lines (Figures 3 and 4).Table 1 Number of cells (%) expressing CSF-1R
ctrl Without FBS csf-1r siRNA Non-coding
CMT-U27 72.10 73.4 15.65*** 75.80
CMT-U309 66.80 70.0 3.00*** 64.40
P114 88.70 73.7 38,45*** 90.85
CMT-W1 80.45 73.6 23.45*** 82.30
CMT-W2 58.70 52.3 23.15*** 64.80
The number of CSF-1R expressing cells obtained with FACS Aria II (Becton Dickinson
the csf-1r specific siRNA treatment and significantly increased after treatment with C
these doses have been observed). Treatment of cells with non-coding siRNA did no
P<0.05 was regarded as significant and marked as *, whereas p<0.01 and p<0.001 w
way ANOVA followed by Tukey HSD post-hoc test were applied.CSF-1R inhibits apoptosis and promotes proliferation of
canine mammary cancer cells
Annexin V analysis revealed that csf-1r specific siRNA
treatment increased the number of apoptotic cells in all in-
vestigated cell lines (Figure 3A, B). The apoptotic effect was
highly significant (p<0.001) in CMT-U27 and CMT-W1 cell
lines (20.5% and 14.85% increase in number of apoptotic
cells, respectively). In CMT-U309, P114 and CMT-W2 cell
lines the increase in the number of apoptotic cells was less
pronounced, however, also significant (2.9%, 6.2% and 5.8%,
respectively). This effect was not obtained when the cancer
cells were treated with scrambled siRNA. In this case, the
obtained results were comparable to the non-transfected
controls. Similarly, treatment of cells with CSF-1 did
not cause any significant effect, however in CMT-U27,
CMT-U309, P114 and CMT-W2 a decrease in the number
of apoptotic cells was noted. Cells cultured in serum-
starved conditions with/without CSF-1 (25 ng/ml) also did
not show any significant difference in the rate of apoptosis
in comparison to control conditions (Figure 5).
Treatment of cells with csf-1r-specific siRNA significantly
decreased their proliferation, assessed based on the number
of Ki-67-positive cells detected using flow cytometric ana-
lysis. The highest effect was observed in CMT-U27 (14.8%
decrease in the number of Ki67-expressing cells). In case of
CMT-U309, P114, CMT-W1 and CMT-W2 cell lines the
decrease amounted to: 7.35%, 3.95%, 8.15% and 6.6%, re-
spectively (Figure 5C).
The stimulating effect of CSF-1 on cell proliferation
was also observed. The highest increase in number of
Ki67-positive cells was observed in CMT-W2, P114 and
CMT-W1 cell lines (9.75%, 9.4% and 7%, respectively). In
CMT-U27 and CMT-U309 cell lines the increase was less
pronounced, namely: 4% and 3.15% respectively (Figure 5C).
CSF-1R enhances canine mammary cancer cells migration
The wound healing assay showed that in all examined
cancer cell lines the knockdown of csf-1r decreased migra-
tory abilities, whereas treatment with CSF-1 (25 ng/ml) in-
creased migration (Figure 6). CMT-U27 cells grown in the
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Figure 1 Expression of CSF-1R at protein level. Expression of CSF-1R examined in canine mammary cancer cell lines using a BD FACSCAria II
(BD Biosciences, USA) and analyzed with FACS Diva software (BD Biosciences). The experiment was conducted three times. A. Representative
overlay histograms of CSF-1R expression in CMT-U27 canine mammary cancer cells (control), and treated with csf-1r specific siRNA and non-
coding siRNA. The overlay histograms were created using Flowing Software (Turku University, Finland), www.flowingsoftware.com.
B. Representative overlay histograms of CSF-1R expression in CMT-U27 canine mammary cancer cells (control), and treated with CSF-1 at the dose
of 25, 50 and 100 ng/ml. The overlay histograms were created using Flowing Software (Turku University, Finland), www.flowingsoftware.com.
C. Representative graphs of the number of CSF-1R expressing cells (CMT-U27) obtained with FACS Aria II (Becton Dickinson). The number of cells
which express CSF-1R is significantly decreased after the csf-1r specific siRNA treatment and significantly increased after treatment with CSF-1 at
the dose of 25, 50 and 100 ng/ml (no significant differences between these doses have been observed). Treatment of cells with non-coding
siRNA did not cause any effect. Error bars refer to S.D. p<0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-hoc test were
applied. D. Representative graphs of the mean fluorescence related to CSF-1R expression in CMT-U27 cell line obtained with FACS Aria II (Becton
Dickinson). The mean expression of CSF-1R is significantly decreased after the csf-1r specific siRNA treatment and significantly increased after
treatment with CSF-1 at the dose of 25, 50 and 100 ng/ml (no significant differences between these doses have been observed). Treatment of
cells with non-coding siRNA did not cause any effect. Error bars refer to S.D. p<0.05 was marked as *, and p<0.001 was marked as ***. One-way
ANOVA followed by Tukey HSD post-hoc test were applied.
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31.49% of the wound during the same period. Further-
more, treatment of CMT-U27 cells with csf-1r-specific
siRNA resulted in a significant decrease in wound healing
abilities of these cells, as only 8.42% of the wound
was closed after six hrs. In case of P114, CMT-W1 and
CMT-W2 cells cultured with CSF-1 a significant percent
of wound was closed after 6 hrs (70.88, 77.54 and 86.79,
respectively), whereas the control cells closed only 45.89%,
55.4% and 74.91% of the wound, respectively. When these
cell lines were treated with csf-1r siRNA not more than16.62%, 31.95% and 40.63% of the wound was closed after
six hrs, respectively. CMT-U309 cells treated with CSF-1
closed 34.62% of the wound after six hrs, whereas the con-
trol cells closed only 24.62% and csf-1r siRNA treated cells
showed only 9.06% of wound closure.
CSF-1R increases canine mammary cancer cells invasion
in matrigel matrix
We have assessed the impact of csf-1r knockdown and
CSF-1 supplementation on growth characteristics of ca-
nine mammary cancer cells on Matrigel matrix (Figure 7).
Table 2 Mean fluorescence related to CSF-1R expression
ctrl Without FBS csf-1r siRNA Non-coding siRNA CSF-1 25 ng/ml CSF-1 50 ng/ml CSF-1 100 ng/ml
CMT-U27 284.0 191.0* 76.00** 306.5 2450*** 2430*** 2616***
CMT-U309 255.0 217.5* 107.0*** 251.0 5114*** 4080*** 4100***
P114 458.5 200.0* 48.50** 537.0 4680*** 4638*** 6178***
CMT-W1 335.0 190.0* 218.5* 383.5 1861** 2268** 1780**
CMT-W2 195.5 130.8* 80.50* 228.5 2448*** 2200*** 2679***
Mean fluorescence related to CSF-1R expression obtained with FACS Aria II (Becton Dickinson). Mean fluorescence of CSF-1R is significantly decreased after the
csf-1r specific siRNA treatment and significantly increased after treatment with CSF-1 at the dose of 25, 50 and 100 ng/ml (no significant differences between
these doses have been observed). Treatment of cells with non-coding siRNA did not cause any effect. The experiment has been conducted in three replicates.
P<0.05 was regarded as significant and marked as *, whereas p<0.01 and p<0.001 was regarded as highly significant and marked as * and ***, respectively. One-
way ANOVA followed by Tukey HSD post-hoc test were applied.
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CMT-U309 and P114 cell lines formed colonies, whereas
CMT-W1 and CMT-W2 cell lines formed branching struc-
tures, which could result from their invasive phenotype, de-
scribed elsewhere [8]. However, we observed that csf-1r
silencing decreased the ability of CMT-W1 and CMT-W2
cells ability to invade the Matrigel and changed their
growth characteristics (they formed colonies not the
branching structures). The addition of CSF-1 to the culture
did not cause any effect on the growth characteristics of
the examined cell lines.
Invasion assay of the most invasive cell lines CMT-W1
and CMT-W2 showed that CSF-1 increased, whereas csf-1r
knockdown decreased their ability to invade the Matrigel
(Figure 8). The fluorescence intensity related to the migra-
tion of CMT-W1 control cells was 324.8, whereas in case
of the CMT-W1 cells treated with csf-1r siRNA and CSF-1
(25 ng/ml) it was 266.07 and 365.53, respectively. The fluor-
escence intensity related to the migration of CMT-W2Figure 2 Expression of CSF-1R at mRNA level. The relative gene
expression level csf-1r in CMT-U27, CMT-U309, P114, CMT-W1 and
CMT-W2 cell lines in control conditions, after siRNA transfection (to
knockdown csf-1r expression) and CSF-1 treatment (25 ng/ml)
determined using Real-time PCR. The results are presented as means
from 3 experiments. Error bars refer to S.D. The statistical analysis
was performed using Prism version 5.00 software (GraphPad
Software, USA). The one-way ANOVA and Tukey HSD post-hoc test
were applied. p<0.05 was regarded as significant and marked as *,
whereas p<0.01 and p<0.001 was regarded as highly significant and
marked as ** and ***, respectively.control cells was 316. When these cells were transfected
with csf-1r-specific siRNA, the intensity decreased to
247.07, whereas the treatment with CSF-1 resulted in an in-
crease of the fluorescence intensity to 382.14.
Discussion
Our results showed that all the examined canine mammary
cancer cell lines expressed CSF-1R. This finding is in ac-
cordance with previously published results, which showed
that CSF-1R is expressed in 100% of canine mammary can-
cers. Moreover, its expression increased in more malignant
and metastatic tumors [10]. However, in humans CSF-1R
is expressed in only about 50% of breast cancers [17]. It
suggests that CSF-1R can be even more important for ca-
nine mammary cancer development than for breast cancer.
We suppose that the differences between CSF-1R expres-
sion in dogs and humans may results from the specificity
of canine ovarian cycle, as there are significant differences
in the course of this cycle among mammalian species. In a
non-pregnant bitch, estrus is usually followed by a pro-
longed luteal phase correlating with pregnancy-like con-
centrations of hormones [14]. This prolonged exposure to
serum progesterone stimulates mammary gland develop-
ment, which is very often accompanied with subsequent
lactation [18]. This pseudo pregnancy is often followed by
development of mammary tumors [19]. Because CSF-1R is
expressed in mammary tissue during pregnancy and lacta-
tion [6], canine epithelial cells may show its expression
more often than in humans.
However, the role of CSF-1R in canine mammary tissue
or cancer has not been investigated yet. Thus, the aim of
our study was to evaluate the role of CSF-1R in biology of
canine mammary cancer cells. We used five various cell
lines and treated them with 1) csf-1r specific siRNA
(to knockdown its expression) and with 2) CSF-1 to stimu-
late the expression of this receptor. Cells were grown
in complete medium for 24 hrs. Then, they were incubated
in the absence of FBS for 24 hrs before being incubated in
RPMI 1640 with 10% FBS and CSF-1 at the concentration
of 25 ng/ml, 50 ng/ml and 100 ng/ml for further 24 hrs
(these doses have been described by other authors, as the
Figure 3 Examination of CSF-1R activation by Western blot. Western blot pictures (A.) and graph (B.) of the CSF-1R activation status in
canine mammary carcinoma cell lines in control conditions (ctrl), in serum-starving conditions (−FBS) and in serum-starving conditions
supplemented with CSF-1 (25 ng/ml) (−FBS/+CSF-1 25 ng/ml). The level of examined proteins was expressed as IOD (integrated optical density)
of protein in arbitrary units with the value obtained using the Odyssey Infrared Imaging System (LI-COR Inc., USA). The results are expressed as
the mean ±SD. The Tukey post-hoc test + ANOVA were applied (Graph Pad v. 5.0), the values differed significantly (p≤0.05) were marked as *,
whereas values differed highly significant (p≤0.01 and p≤0.001) were marked as ** or ***, respectively.
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http://www.biomedcentral.com/1746-6148/9/65most effective ones [6,20]). Flow cytometric analyses re-
vealed that the siRNA sequences used in this study de-
creased both: the number of cells expressing CSF-1R and
mean fluorescence related to its expression (Tables 1 and
2; Figure 1). We also observed that serum-starved condi-
tions (RPMI-1640 without addition of FBS) caused a
significant decrease in the mean expression and phos-Figure 4 Examination of CSF-1R activation by Immunohistochemistry
mammary cell lines (CMT-U27, CMT-U309, P114, CMT-W1 and CMT-W2) gro
serum-starving conditions and supplemented with CSF-1 (25 ng/ml) (−FBS
CMT-W1 cell line (in control conditions, serum-starving conditions and seru
obtained using Olympus BX60 microscope (at the magnification of 200x). T
slide were analyzed. The colorimetric intensity of the IHC-stained antigen s
Microimage™ Image Analysis, software version 4.0 for Windows, USA) and
optical density (IOD). The statistical analysis was performed using Prism ver
post-hoc tests were applied to analyze the optical density in cell lines. p<0
differed highly significant (p≤0.01 and p≤0.001) were marked as ** or ***, rphorylation of CSF-1R in cancer cells (Figures 3 and 4),
whereas it did not affect the number of cells expressing
CSF-1R. These results suggest that FBS can contain CSF-1
or other growth factors that stimulate CSF-1R. However,
the autocrine stimulation of cancer cells cannot be ruled
out. Supplementation of cells growth medium or medium
without FBS with CSF-1 caused an significant increased. A. The graph of mean optical density of p-CSF-1R (Tyr 723) in canine
wn in control conditions (ctrl), serum-starving conditions (−FBS) and in
/+CSF-1 25 ng/ml). B. Representative pictures of p-CSF-1R expression in
m starving conditions and supplemented with CSF-1 (25 ng/ml)
he p-CSF-1R is reflected as brown precipitate. Ten pictures in each
pots was counted by a computer-assisted image analyzer (Olympus
the antigen spot color intensity is expressed as mean pixel integrated
sion 5.00 software (GraphPad Software, USA). The ANOVA + Tukey
.05 was regarded as significant and marked as *, whereas values
espectively.
Figure 5 CSF-1R inhibits apoptosis and promotes proliferation in canine mammary cancer cells. The effect of csf-1r specific siRNA and
CSF-1 treatment of canine mammary cancer cell lines (CMT-U27, CMT-U309, P114, CMT-W1 and CMT-W2) on apoptosis (A). The number of
apoptotic cells represented as a percentages of Annexin-V-positive cells obtained with FACS Aria II (Becton Dickinson) is significantly increased
after csf-1r silencing. Treatment of cells neither with non-coding siRNA with transfection reagent nor with CSF-1 cause any significant effect
comparing to the control. Similarly, cell culture neither in serum-starved conditions (RPMI-1640 without FBS) nor in serum-starved conditions with
CSF-1 caused any effect. Error bars refer to S.D. p<0.05 was marked as *, p<0.01 was marked as ** and p<0.001 was marked as ***. One-way
ANOVA followed by Tukey HSD post-hoc test were applied. (B) The representative histograms and cytograms of CMT-U27 cell line double stained
with AnnexinV-FITC and PI. Cells located on the right side of the histograms represented apoptotic cells. On the cytograms are showed normal,
early apoptotic, late apoptotic and necrotic cells. Left bottom quadrant shows normal cells, top left quadrant shows necrotic cells (damaged cell
membrane but no phosphatydilserine exposure), right bottom quadrant shows the early apoptotic cells (intact cell membrane) and top right
quadrant shows cells in late stage of apoptosis. The effect of csf-1r gene silencing and CSF-1 (25 ng/ml) treatment on proliferation (C) of canine
mammary cancer cells was assessed by Ki67 test (BD Bioscience, USA). The number of cycling cells represented as a percentage of Ki67-positive
cells is significantly decreases after the transfection whereas significantly increased after CSF-1 treatment. Error bars refer to S.D. The statistical
analysis was performed using Prism version 5.00 software (GraphPad Software, USA). One-way ANOVA followed by Tukey HSD post-hoc test were
applied. p<0.05 was marked as *, p<0.01 was marked as ** and p<0.001 was marked as ***.
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Figure 6 Role of CSF-1R signaling in canine mammary cancer cells migration assessed by “wound healing” assay. A. Representative
pictures of migration (wound closing) of CMT-U27 cell line: control cells, transfected cells (with csf-1r specific siRNA) and cell treated with CSF-1
(25 ng/ml) at 0 and 6 hrs after the scratch was made. B. The graphs of % of wound closure after the 2, 4 and 6 hrs of migration. The pictures
were taken using phase-contrast microscopy (Olympus). The statistical analysis was performed using Prism version 5.00 software (GraphPad
Software, USA). The one-way ANOVA was applied to analyze the results. p<0.05 was regarded as significant and marked as *, whereas p<0.01 and
p<0.001 were regarded as highly significant and marked as ** and ***, respectively.
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Figures 1, 2, 3 and 4), however not in a dose dependent
manner. That is why we decided to use the lowest effective
dose: 25 ng/ml, in following experiments. Similarly, this
dose was used by other authors for assessment of the role
of CSF-1R in biology of breast cancer cell lines [6].
The impact of RNA interference and CSF-1 supplemen-
tation on csf-1r expression was also confirmed using
Real-time qPCR. However, there were some differences
between the observed level of csf-1r mRNA and CSF-1R
protein. These results are not surprising, as it has been
reported that in experiments with the use of RNAi the
correlation between the gene and protein expression levels
can be poor, although the compatibility between these two
levels of expressions may be good, based on ‘present’ vs.
‘absent’ findings [21,22].
We found that both: knockdown of csf-1r and an in-
crease of its expression after CSF-1 treatment have a sig-
nificant impact on cancer cells. The treatment of cell with
CSF-1 mimicked the presence of macrophages in the
tumor microenvironment, as our previous findings have
demonstrated that the presence of macrophages in the
tumor microenvironment increases CSF-1R expression in
cancer cells [8].
The results of our present study showed that knock-
down of CSF-1R increased the number of apoptotic cells
(Figure 5A, B). This was not related with the toxic effect
of transfection reagents or procedure because in cells
treated with non-coding siRNA and transfection reagent
the number of apoptotic cells did not differ from the con-
trol cells. CSF-1 treatment neither caused any significant
effect on apoptosis in cancer cells grown in normal
medium, nor in cells grown in serum-starved conditions.
Interestingly, blockade of CSF-1/CSF-1R signaling in-
creased the number of apoptotic cells dramatically. Up-to-date there are no available reports regarding the impact
of CSF-1R on apoptosis in cancer cells. However, an inter-
esting study showed that blockade of CSF-1R by BAY 43-
9006/Sorafenib increased apoptosis in Hodgkin-/Reed-
Sternberg cells [23] and it enhanced the activity of conven-
tional chemotherapeutics.
In all examined cell lines, we observed an increase in
proliferation induced by CSF-1. The number of cells ex-
pressing Ki67 antigen was almost 10% higher in P114 and
CMT-W2 cell lines (Figure 5C). However, CSF-1R silen-
cing significantly decreased proliferation in all examined
cell lines. The number of cells expressing Ki67 antigen
was 15% decreased in CMT-U27 cell line, whereas in the
rest of cell lines the decrease was of 4-8% (Figure 3C). It
has been shown previously that in breast cancer cell lines
administration of CSF-1 activates cyclin D1, as a conse-
quence of ERK1/2 activation [17,24].
There are few reports of CSF-1R role in tumor metasta-
sis. Sapi et al. [25] injected CSF-1R overexpressing cancer
cells into mice and observed increased lung metastasis in
these animals. Our own results also confirm these findings,
as we observed the highest expression of CSF-1R in the
most malignant and metastatic mammary tumors [10]. Re-
sults of prof. Condeelis group [9] indicate that both auto-
crine and paracrine CSF-1 loops significantly contribute to
dissemination of cancer cells and progression in human
breast cancer.
Considering invasion and migration as steps in the
metastatic cascade our results confirm that CSF-1R signal-
ing promotes this process. We showed that treatment of
cells with CSF-1 as well as csf-1r knockdown had signifi-
cant effect on cancer cells migration. The “wound healing”
assay showed that csf-1r specific siRNA treatment of
cells significantly inhibited cancer cells migration (about
15-58% difference in “wound” closure between control
Figure 7 An impact of csf-1r silencing and CSF-1 treatment on 3D growth of canine mammary cancer cell lines. Growth characteristics of
CMT-U27 (A), CMT-U309 (B), P114 (C), CMT-W1 (D) and CMT-W2 (E) cell lines (phase contrast micrographs) grown on Matrigel matrix for 24 hours
in control conditions, transfected with csf-1r specific siRNA and treated with CSF-1 (25 ng/ml).
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CSF-1 treatment increased cells migration, causing about
10-34% difference in “wound” closure between control
cells and cells treated with CSF-1 (Figure 6). These find-
ings are compatible with the results of our previous study
on the effect of co-culture of cancer cells and tumor-
associated macrophages. We showed that the presence of
macrophages in cancer cell microenvironment accelerated
“wound” closure of about 30% [8]. Based on these findings
we can conclude that the used CSF-1 dose mimicked the
presence of macrophages in cancer cells environment re-
garding the CSF-1R signaling.
Our results showed also that csf-1r RNAi knockdown
caused significant changes in growth characteristics onMatrigel matrix of canine cancer cells (Figure 7). The
growth characteristics of examined cells on extracellular
matrix components have previously been published [4].
The present results showed that only two of the cell lines
form branches and invade matrix. These two highly inva-
sive cell lines have been previously described as “metastatic”
[8]. Knockdown of csf-1r caused changes in growth of these
two highly invasive cell lines, as most of them did not in-
vade Matrigel matrix or form branches, but grew in col-
onies. The cells were seeded on Matrigel matrix 48 hrs
after transfection and then observed after the next 24 hrs
(that is: 72 hrs post transfection). As siRNA gene silencing
is a transient effect [23], after the next 24 hrs they started
to grow in their normal manner (data not showed).
Figure 8 Invasion assay of highly invasive canine mammary cancer cell lines after treatment with csf-1r specific siRNA and CSF-1
(25 ng/ml). A. The graph of fluorescence intensity related to invasion of canine mammary cancer cell lines (CMT-W1 and CMT-W2) grown in
control conditions (ctrl), transfected with csf-1r specific siRNA and treated with CSF-1 (25 ng/ml). The statistical analysis was performed using
Prism version 5.00 software (GraphPad Software, USA). Error bars refer to S.D. The unpaired t-test was applied to analyze the results. p<0.05 was
regarded as significant and marked as *. B. Pictures of CMT-W1 cells (green fluorescence) obtained using Olympus BX60 microscope examined in
control conditions and after transfection (csf-1r specific siRNA) and CSF-1 (25 ng/ml) treatment.
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fect on examined cell lines (Figure 7). This is a good
method to assess if the cell line invades the matrix or not,
however, this is not an objective method to assess the level
of invasion. To assess more accurately the effect of CSF-1
on canine mammary cancer cells invasion, we conducted
the invasion assay of highly invasive cell lines in Boyden
chambers (Figure 8). Our results confirmed that the de-
creased CSF-1R expression is accompanied by the lower
ability of cancer cells to invade matrix, whereas the presence
of CSF-1 in the culture medium increased canine mammary
cancer cells invasion in Matrigel matrix (Figure 8).
The findings of our study suggest that blocking of
CSF-1R in patients may suppress tumor development and
invasion by acting on cancer cells itself. Moreover, because
mammary tumor microenvironment is rich in tumor-
associated macrophages, which express CSF-1R (they have
resident-type macrophage phenotype [26]), this approach
could also affect tumor-associated macrophages that are an
important element in cancer development and invasion.
Conclusions
In conclusion, the evidence of the expression and func-
tional role of the CSF-1R in canine mammary cancercells indicate that CSF-1R targeting may be a good
therapeutic approach.
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